

A Rapid and Sensitive High-Performance Liquid Chromatography–Electrospray Ionization–Triple Quadrupole Mass Spectrometry Method for the Quantitation of Oxycodone in Human Plasma

Michael Dawson^{1,*}, Bronwyn Fryirs², Tamsin Kelly¹, Jim Keegan¹, and Laurence E. Mather²

¹Department of Chemistry, Materials and Forensic Science, University of Technology, Sydney, P.O. Box 123, Broadway, N.S.W. 2007, Australia and ²Department of Anaesthesia and Pain Management, University of Sydney, Royal North Shore Hospital, St. Leonards, N.S.W. 2065, Australia

Abstract

A sensitive method for the determination of oxycodone concentrations in plasma by high-performance liquid chromatography (HPLC)–electrospray ionization–triple quadrupole mass spectrometry is described. The method is rugged, reliable, selective, and rapid with a run time of 2 min. One milliliter of plasma is made basic and extracted with 2-mL duplicate portions of 2% isoamyl alcohol in *n*-butyl chloride. The combined extracts are then evaporated to dryness, reconstituted in 100 μ L of the mobile phase (15% methanol–85% water containing 0.1% acetic acid), and injected onto the HPLC. The limit of quantitation is 1 ng/mL, and the estimated limit of detection is 33 pg/mL (signal-to-noise = 3). Standard curves are linear over the range of 1 to 100 ng/mL with all correlation coefficient values greater than 0.9989. The method is used to determine the concentration of oxycodone in human plasma following the intravenous infusion of doses ranging from 5 to 15 mg in which the analysis of over 3000 plasma samples is required.

Introduction

Oxycodone (4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one) (Figure 1) is a potent opioid agonist with a dose-dependent analgesic effect (1) comparable with morphine (Figure 1) (2) and has been available for clinical use since 1915 (3). Clinically, oxycodone is administered alone as immediate or modified release products or in combination with mild analgesics (2) for the management of moderate to severe pain.

The quantitation of oxycodone concentrations in biological fluids by gas chromatography (GC) is not straightforward because of the need to derivatize the 14-hydroxyl group (3–6), and none of

the derivatives evaluated by us exhibited satisfactorily on machine stability. Similarly, the fronting and tailing of the oxycodone peak when high-performance liquid chromatography (HPLC) is used causes reductions in sensitivity and selectivity. Broglé (7) investigated the causes of the peak fronting of oxycodone under a number of HPLC conditions. It was concluded that the cause of peak fronting was not the coexistence of keto–enol tautomers in the solutions analyzed, but rather the presence of ketone–gemdiol and ketone hemi-ketal equilibria species resulting from reactions with water and methanol, respectively, in the acidic mobile phase (Figure 2). These equilibria are temperature dependent, and fronting can be minimized by raising the column temperature.

Literature methods for the determination of oxycodone also include radioimmunoassay and thin-layer chromatography




Figure 1. The chemical structure of (A) oxycodone, (B) naloxone, and (C) morphine.




Figure 2. Equilibria between (A) the ketone–gemdiol, (B) oxycodone, and (C) ketone–hemiketal of oxycodone.

* Author to whom correspondence should be addressed; email michael.dawson@uts.edu.au.

range of 1.8 to 3 ng/mL, but no data on the limit of quantitation have been provided. A GC–ECD method, which included a derivatization step with heptafluorobutylimidazole, had the reported lowest point on the standard curve of 10 ng/mL (17).

Various GC–mass spectrometry (MS) methods report similar sensitivity to HPLC–ECD and GC–NPD methods. One GC–MS method for measuring oxycodone in urine had a limit of quantitation of 25 ng/mL after extensive sample preparation, which included sequential derivatization with 2% methoxyamine in pyridine followed by propionic anhydride (5). Another described a method based on the GC–MS analysis of the trimethylsilyl ether derivatives of oxycodone that was linear over the range of 150 to 1500 ng/mL (4). Others have reported methods in which sample preparation included derivatization with acetic anhydride–pyridine. The linear ranges of the methods were 50–1000 ng/mL (6) and 0.2–100 ng/mL (2).

Although many analytical methods have been reported in the literature for the determination of oxycodone in biological fluids, none were suitable for the purposes of our study, which required the rapid analysis of over 3000 plasma samples. Reported methods either lacked the desired degree of sensitivity or were excessively time consuming with respect to work-up and HPLC run time.

The method described in this study has comparable limits of quantitation to the more sensitive methods previously reported in the literature, but has significant advantages (such as the sample preparation was simple and the run time very short). Sample preparation consisted of the addition of an internal standard (naloxone) followed by the liquid–liquid extraction of the plasma sample and a subsequent concentration of the extract prior to injection onto the liquid chromatograph (LC)–MS–MS. Triple quadrupole MS provided unsurpassed selectivity in which the analyte and internal standard were separated by mass and not time. Retention times were 1.30 min for naloxone and 1.41 min for oxycodone, and the run time was 2 min, thus allowing for very high throughput of samples.

The mobile phase consisted of 15% methanol–85% water (v/v) with 0.1% acetic acid, and the column temperature was 60°C. These conditions produced minimal fronting and tailing with almost symmetrical peaks.

A highly sensitive assay was required for pharmacokinetic studies (dose range from 5 to 15 mg), and in order to generate the required data it was necessary to follow the time course of oxycodone for as long as possible after the administration of each dose. The method developed and reported in this study is more sensitive, more selective, less complicated, and has a significantly shorter analysis time than other published assays, allowing for the rapid and accurate determination of very low levels of oxycodone in plasma.

Experimental

Materials and reagents

Reference samples of oxycodone hydrochloride and naloxone hydrochloride were obtained from Boots (Sydney, Australia) and Sigma (St. Louis, MO), respectively. HiPerSolv-grade *n*-butyl

chloride was obtained from BDH Chemicals (Melbourne, Australia); SurfaSil was obtained from Pierce (Rockford, IL); and all other chemicals used were analytical-reagent grade. Water was purified by a Milli-Q system obtained from Millipore (Sydney, Australia).

All glassware was supplied by Alltech (Sydney, Australia). A Searle vortex mixer (Buchler Instruments, Ft. Lee, NJ) and a Medos JAK vacuum evaporator (Dynavac Engineering, Sydney, Australia) were used in the sample preparation.

Preparation of glassware

Glassware was silanized by immersion in a 5% solution of SurfaSil in *n*-hexane for 10 min and then rinsed with acetone and dried in an oven at 100°C for 1 h.

Instrumentation

Analyses were performed using a PerkinElmer (Melbourne, Australia) Series 200 autosampler, micro PerkinElmer series 200 LC pump, vacuum degasser, and PerkinElmer SCIEX API 365 LC–MS–MS with Turbo IonSpray. The Zorbax SB-C18 5- μ m column (50- × 2.1-mm i.d.) (Agilent, Melbourne, Australia) was maintained at 60°C. The mobile phase consisted of 15% methanol–85% water containing 0.1% acetic acid, the flow rate was 0.2 mL/min, and the injection volume was 10 μ L.

The MS was run in multiple reaction monitoring mode. The nebulizing gas flow rate of the Turbo IonSpray was 1.25 L/min. The electrospray ion source voltage was 5000 V, the orifice voltage was +30 V, and the source temperature was 300°C. The ring voltage was +220 V, the Q0 energy was –10 V, and RO2 was –35 V in order to give a collision energy of 25 V for both oxycodone and naloxone. The curtain gas was nitrogen at a flow rate of 1.25 L/min. The ions monitored were m/z 316.1 (Q1) \rightarrow 298.1 (Q3) for oxycodone and m/z 328.1 (Q1) \rightarrow 310.1 (Q3) for naloxone. The dwell time was 200 ms for both oxycodone and naloxone.

Sample preparation

Blood samples obtained from healthy human subjects before and after receiving oxycodone were placed in heparinized blood-collecting tubes and centrifuged at 1500 g for 10 min. The plasma was separated and stored at –20°C until analysis.

A stock solution of 10 mg/mL oxycodone (as the hydrochloride) was prepared in Milli-Q water. Standards in plasma were then prepared by adding volumes of stock solution to drug-free plasma to give final concentrations covering the range of 1 to 100 ng/mL. The working internal standard solution (670 ng/mL naloxone hydrochloride) was prepared in Milli-Q water.

One-milliliter aliquots of the plasma samples and the plasma oxycodone standard solutions were pipetted into 4-mL glass vials containing the internal standard (naloxone hydrochloride, 10 μ L, 6.7 ng) and made alkaline to pH 9 with 200 μ L carbonate buffer. The carbonate buffer was prepared from a saturated sodium hydrogen carbonate solution, which was adjusted to pH 9 with a saturated sodium carbonate solution. The extraction solvent, 2% isoamyl alcohol in *n*-butyl chloride (2 mL), was added, and the mixture was vortex mixed for 10 min followed by centrifugation at 2000 g for 5 min. The samples were frozen at –80°C for 20 min and the organic layer decanted into a 2-mL glass vial and evaporated to dryness under vacuum at 40°C. The sample was re-

extracted, and the extraction residues were combined and reconstituted in a 100- μ L mobile phase, vortex mixed (30 s), centrifuged (1 min), and then transferred into a 250- μ L silanized glass insert. An aliquot (10 μ L) was injected onto the HPLC.

Results and Discussion

Sample preparation considerations

In order to increase the sensitivity of this assay, several factors were addressed. First, all glassware was deactivated with a silanizing reagent to minimize the loss of oxycodone through binding to active sites on the glassware. Second, ultrahigh-purity solvents were used to minimize solvent impurity interferences. Third, 2% isoamyl alcohol in *n*-butyl chloride was used as the extraction solvent because it caused no emulsification with plasma, which was noted with other extraction solvents evaluated.

Chromatography

Chromatographic conditions were optimized to provide both short retention times and an adequate peak shape in order to allow for the quantitation of oxycodone and naloxone. Factors

were taken into account when selecting the final conditions such as our observation that increasing concentrations of methanol in the mobile phase reduced the sensitivity of oxycodone because of mobile phase ion suppression. Naidong (18) reported that mobile phases with little organic component resulted in poor spray conditions because of the high surface tension of the aqueous droplets, thus adversely affecting sensitivity. The methanol content selected in this study was that which gave short retention times without adversely affecting sensitivity.

It was also found that the addition of 0.1% acetic acid not only improved the retention time stability of both analytes, but also provided an increase in sensitivity. The mobile phase selected for this assay provided the required sensitivity with both short retention times and nearly symmetrical peaks.

Peak symmetry was calculated using the 4.4% peak height/peak asymmetry factor. Five replicate chromatograms of extracts from plasma containing 100 ng/mL oxycodone gave an asymmetry value of 1.4, which indicated that there was only slight tailing associated with these peaks.

The sensitivity of the assay was excellent as shown in Figure 3, which shows the chromatograms of an extract from 1 mL of plasma spiked with 1 ng oxycodone (Figure 3C) and 6.7 ng naloxone (Figure 3D) and a representative blank for each transition (Figures 3A and 3B).




Figure 3. Chromatograms of an extract from (A and B) 1 mL blank plasma and (C) 1 mL plasma spiked with 1 ng oxycodone and (D) 6.7 ng naloxone. The transitions were oxycodone (m/z 316 \rightarrow 298) and naloxone (m/z 328 \rightarrow 310).

Electrospray mass spectra

The fragmentation of the product ions of oxycodone and naloxone are shown in Figures 4A and 4B, respectively. The predominant peaks for oxycodone (Figure 4A) were m/z 316.1 (corresponding with MH^+) and m/z 298.1 (corresponding with $MH^+ - H_2O$). The predominant peaks for naloxone (Figure 4B) were m/z 328.1 (MH^+) and m/z 310.1 (corresponding with $MH^+ - H_2O$). Q3 scan conditions were optimized by infusing a solution of analyte (oxycodone or naloxone) in the mobile phase via a syringe pump (2.5 mL/h) and using Autotune Optimisation software.

Retention times

The retention times for oxycodone and naloxone (internal standard) were 1.41 and 1.30 min, respectively.




Figure 4. The collision activated decomposition spectrum of the protonated molecule of (A) oxycodone (m/z 316.1) and (B) naloxone (m/z 328.1).

Linearity

Standard curves covering the concentration range of 1 to 100 ng/mL oxycodone in plasma were found to be linear. Six standard curves had correlation coefficient values ranging from 0.9989 to 0.9999.

Limit of quantitation and limit of detection

The limit of quantitation was 1 ng/mL and the limit of detection was 33 pg/mL (signal-to-noise = 3).

Within-run precision

A measure of within-run precision was estimated from the coefficient of variation of samples ($n = 6$) processed in the same batch and analyzed on the same day. An assay of six replicate samples at 1, 10, and 100 ng/mL gave coefficients of variation of 8.6%, 1.9%, and 1.9%, respectively.

Between-run precision

A measure of between-run precision was estimated by averaging the coefficients of variation from the analysis of six replicate samples run over 3 days ($n = 18$). The average between-run precision was 11.2%, 4.4%, and 3.0% for samples at concentrations of 1, 10, and 100 ng/mL, respectively.

Accuracy

Accuracy was determined as a percentage of calculated concentration over the actual concentration. An assay of six replicate samples at 1, 10, and 100 ng/mL gave calculated accuracy values of 126.5%, 98.6%, and 100.1%, respectively.

Selectivity

An analysis of blank plasma samples showed there were no interfering peaks at the elution time of either oxycodone or the internal standard.

Stability

Smith (11) reported that oxycodone was stable in plasma samples stored at -20°C for up to 6 months.

Extracted oxycodone samples were stable for at least 24 h at room temperature. There was no significant difference ($\alpha = 0.05$) for samples reanalyzed after storage in the autosampler carousel for 24 h at concentrations of 1, 10, and 100 ng/mL ($n = 6$ at each concentration).

Samples were stable following three freeze/thaw cycles. There




Figure 5. The oxycodone plasma concentration versus time profile following an intravenous dose of 5 mg oxycodone.

was no significant difference ($\alpha = 0.05$) for samples reanalyzed after three freeze/thaw storage cycles at concentrations of 1, 10, and 100 ng/mL ($n = 6$ at each concentration).

Application of the method

Clinical studies were carried out in which an intravenous infusion dose of oxycodone was given for 60 min (dose concentrations ranged from 5 to 15 mg). Samples were taken over a period of 3 h after the dose. A blank sample was taken prior to dosing to determine whether there were any interfering ions. None of the blank samples for the subjects enrolled in the study contained interfering ions at the two transitions studied (i.e., m/z 316.1 \rightarrow 298.1 and m/z 328.1 \rightarrow 310.1). It was possible to quantitate oxycodone levels over the period for which respiratory data were gathered for all subjects enrolled in the study. A typical oxycodone concentration-time profile following a single intravenous infusion of 5 mg is shown in Figure 5.

Conclusion

The LC–electrospray ionization–MS–MS method described has been used to process more than 3000 plasma samples. All calibration curves had a correlation coefficient greater than 0.9989 over the plasma concentration range of 1 to 100 ng/mL. Although some previously reported methods have achieved similar limits of quantitation, the method reported in this study requires significantly less sample preparation, and the very short run time allows for very high sample throughput.

Acknowledgments

The authors are pleased to acknowledge the contributions of Ms. Xiao Qing Gu.

References

1. J. Mandema, R. Kaiko, B. Oshlack, R. Reder, and D. Stanski. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. *Br. J. Clin. Pharm.* **42**: 747–56 (1996).
2. R. Kaiko, D. Benziger, R. Fitzmartin, B. Burke, R. Reder, and P. Goldenheim. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. *Clin. Pharmac. Ther.* **59**: 52–61 (1996).
3. R. Poyhia, A. Vainio, and E. Kalso. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. *J. Pain Sympt. Mgmt.* **8**: 63–67 (1993).
4. W. Nowatzke, J. Zeng, A. Saunders, A. Bohrer, J. Koenig, and J. Turk. Distinction among eight opiate drugs in urine by gas chromatography–mass spectrometry. *J. Pharm. Biomed. Anal.* **20**: 815–28 (1999).
5. R. Meatherall. GC–MS confirmation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in urine. *J. Anal. Toxicol.* **23**: 177–86 (1999).
6. W. Huang, W. Andollo, and W.L. Hearn. A solid phase extraction technique for the isolation and identification of opiates in urine.

- J. Anal. Toxicol.* **16**: 307–10 (1992).
7. K. Brogle, R.M. Ornaf, D. Wu, and P.J. Palermo. Peak fronting in reversed-phase high-performance liquid chromatography: a study of the chromatographic behaviour of oxycodone hydrochloride. *J. Pharm. Biol. Anal.* **19**: 669–78 (1999).
 8. D.J. Dietzen, J. Koenig, and J. Turk. Facilitation of thin-layer chromatographic identification of opiates by derivatization with acetic anhydride or methoxyamine. *J. Anal. Toxicol.* **19**: 299–303 (1995).
 9. E.J. Cone, S. Dickerson, B.D. Paul, and J.M. Mitchell. Forensic drug testing for opiates. IV. Analytical sensitivity, specificity, and accuracy of commercial urine opiate immunoassays. *J. Anal. Toxicol.* **16**: 72–78 (1992).
 10. M.L. Smith, R.O. Hughes, B. Levine, S. Dickerson, W.D. Darwin, and E.J. Cone. Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography–mass spectrometry. *J. Anal. Toxicol.* **19**: 18–26 (1995).
 11. M.L. Smith, J.A. Watt, G.P. Mapp, and T. Cramond. Quantitation of oxycodone in human plasma using high-performance liquid chromatography with electrochemical detection. *Ther. Drug Monit.* **13**: 126–30 (1991).
 12. A.W. Wright, J.A. Lawrence, M. Lu, T. Cramond, and M.T. Smith. Solid-phase extraction method with high-performance liquid chromatography and electrochemical detection for the quantitative analysis of oxycodone in human plasma. *J. Chromatogr. B* **712**: 169–75 (1998).
 13. J.J. Schneider, E.J. Triggs, D.W. Bourne, I.D. Stephens, and A.M. Haviland. Determination of oxycodone in human plasma by high-performance liquid chromatography with electrochemical detection. *J. Chromatogr.* **308**: 359–62 (1984).
 14. R.P. Kapil, P.K. Padovani, S.Y. King, and G.N. Lam. Nanogram level quantitation of oxycodone in human plasma by capillary gas chromatography using nitrogen–phosphorus detection. *J. Chromatogr.* **577**: 283–87 (1992).
 15. N.L. Renzi and J.N. Tam. Quantitative GLC detection of oxycodone in human plasma. *J. Pharm. Sci.* **68**: 43–45 (1979).
 16. E. Kalso, A. Vainio, M.J. Matttila, P.H. Rosenberg, and T. Seppala. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. *Pharm. Tox.* **67**: 322–28 (1990).
 17. S.H. Weinstein and J.C. Gaylord. Determination of oxycodone in plasma and identification of a major metabolite. *J. Pharm. Sci.* **68**: 527–28 (1979).
 18. W. Naidong, J.W. Lee, X. Jiang, M. Wehling, J.D. Hulse, and P.P. Lin. Simultaneous assay of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma using normal-phase liquid chromatography–tandem mass spectrometry with a silica column and an aqueous organic mobile phase. *J. Chromatogr. B* **735**: 255–69 (1999).

Manuscript accepted September 28, 2001.